Bright Minds Biosciences (DRUG) Net Cash Flow (2020 - 2026)

Bright Minds Biosciences has reported Net Cash Flow for 7 years, with the latest figure at $159.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 8553.58% year-over-year to $159.9 million; the trailing twelve-month figure through Mar 2026 stood at $180.4 million (up 379.88% YoY), and the FY2025 full-year result was $55.9 million, up 7429.91% from the prior year.
• Net Cash Flow for Q1 2026 stood at $159.9 million, up from $5.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $159.9 million in Q1 2026, with the low at -$15.3 million in Q3 2022.
• Historically, Net Cash Flow has averaged $12.1 million across 5 years, with a median of $1.2 million in 2023.
• Annual changes were most pronounced in 2025 — Net Cash Flow slumped 4178.12% — and 2026, when it surged 8553.58%.
• Bright Minds Biosciences' Net Cash Flow stood at $3.6 million in 2022, then slumped by 65.53% to $1.2 million in 2023, then soared by 2968.79% to $38.3 million in 2024, then plunged by 85.83% to $5.4 million in 2025, then surged by 2842.94% to $159.9 million in 2026.
• The last three Net Cash Flow figures came in at $159.9 million (Q1 2026), $5.4 million (Q4 2025), and $23.3 million (Q3 2025), per Business Quant data.